Surgery for primary hyperparathyroidism

Cancer

Volumn 120, Issue 23, 2014, Pages 3602-3616

  Callender, Glenda G ^a   Udelsman, Robert ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Minimally invasive surgery; Parathyroid surgery; Parathyroidectomy; Primary hyperparathyroidism; Reopertive parathyroidectomy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CINACALCET; CONTRAST MEDIUM; FUROSEMIDE; IODINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

CLINICAL EVALUATION; DISEASE SEVERITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; IMAGE QUALITY; INCIDENCE; MINIMALLY INVASIVE SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARATHYROID CARCINOMA; PARATHYROID DISEASE; PARATHYROIDECTOMY; PATIENT CARE; PEROPERATIVE CARE; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; RECURRENT DISEASE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WESTERN HEMISPHERE; ADENOMA; DIAGNOSTIC USE; ECHOGRAPHY; HYPERPARATHYROIDISM, PRIMARY; PARATHYROID GLAND; PARATHYROID NEOPLASMS; PROCEDURES; SCINTISCANNING; SURGERY;

ADENOMA; HUMANS; HYPERPARATHYROIDISM, PRIMARY; PARATHYROID GLANDS; PARATHYROID NEOPLASMS; PARATHYROIDECTOMY; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84913605418     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28891     Document Type: Review

References (101)

1. Sivula A, Ronni-Sivula H. The changing picture of primary hyperparathyroidism in the years 1956-1966. Ann Chir Gynaecol. 1984; 73:319-324.
2. Heath H III, Hodgson S.F., Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980; 302:189-193.
3. Lundgren E, Rastad J, Thurfjell E., et al. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery. 1997; 294:287-294.
4. Jorde R, Bonaa KH, Sundsfjord J. Primary hyperparathyroidism detected in a health screening. The Tromso Study. J Clin Epidemiol. 2000; 53:1164-1169.
5. Soreide JA, van Heerden JA, Grant CS, et al. Characteristics of patients surgically treated for primary hyperparathyroidism with and without renal stones. Surgery. 1996; 120:1033-1037.
6. Silverberg SJ, Bilezikian JP, Bone H.G., et al. Therapeutic controversies in primary hyperparathyroidism. J Clin Endocrinol Metab. 1999; 84:2275-2285.
7. Walgenbach S, Hommel G, Junginger T. Outcome after surgery for primary hyperparathyroidism: ten-year prospective follow-up study. World J Surg. 2000; 24:564-569.
8. Eigelberger MS, Clark OH. Surgical approaches to primary hyperparathyroidism. Endocrinol Metab Clin North Am. 2000; 29:479-502.
9. NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Intern Med. 1991; 114:593-597.
10. Bilezikian JP, Potts JT, Fuleihan G, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 2002; 87: 5353-5361.
11. Bilezikian JP, Khan AA, and Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009; 94:335-339.
12. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement and guidelines from the fourth international workshop. J Clin Endocrinol Metab. 2014, In Press.
13. Clark OH, Wilkes W, Siperstein A.E., Duh QY. Diagnosis and management of asymptomatic hyperparathyroidism: safety, efficacy, and deficiencies in our knowledge. J Bone Miner Res. 1991; 6:S135-S142.
14. Ronni-Sivula H, Sivula A. Long-term effect of surgical treatment on the symptoms of primary hyperparathyroidism. Ann Clin Res. 1985; 17:141-147.
15. Okamoto T, Gerstein HC, Obara T. Psychiatric symptoms, bone density and non-specific symptoms in patients with mild hypercalce-mia due to primary hyperparathyroidism: a systematic overview of the literature. Endocr J. 1997; 44:367-374.
16. Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperpara-thyroidism. World J Surg. 1998; 22:513-518.
17. Hasse C, Sitter H, Bachmann S., et al. How asymptomatic is asymptomatic primary hyperparathyroidism? Exp Clin Endocrinol Diabetes. 2000; 108:265-274.
18. Purnell DA, Smith LH, Scholz D.A., et al. Primary hyperparathyroid-ism: a prospective clinical study. Am J Med. 1971; 50:670-678.
19. Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroid-ism: 10-year prospective study. Mayo Clin Proc. 1981; 56:473-478.
20. Silverberg SJ, Shane E, Jacobs T.P., et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999; 341:1249-1255.
21. Rubin MR, Bilezikian JP, McMahon D.J., et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008; 93:3462-3470.
22. Redman C, Bodenner D, Stack B Jr. Role of vitamin D deficiency in continued hyperparathyroidism following parathyroidectomy. Head Neck. 2009; 31:1164-1167.
23. Grubbs EG, Rafeeq S, Jimenez C., et al. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery. 2008; 144:852-858.
24. Adler JT, Sippel RS, Chen H. 25-Hydroxyvitamin D status does not affect intraoperative parathyroid hormone dynamics in patients with primary hyperparathyroidism. Ann Surg Oncol. 2010; 17:2958-2962.
25. Press D, Politz D, Lopez J., Norman J. The effect of vitamin D levels on postoperative calcium requirements, symptomatic hypocalce-mia, and parathormone levels following parathyroidectomy for primary hyperparathyroidism. Surgery. 2011; 150:1061-1068.
26. Pappu S, Donovan P, Cheng D., Udelsman R. Sestamibi scans are not all created equally. Arch Surg. 2005; 140:383-386.
27. Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009; 94:351-365.
28. Barczynski M, Golkowski F, Konturek A., et al. Technetium-99m-sestamibi subtraction scintigraphy versus ultrasonography combined with a rapid parathyroid hormone assay in parathyroid aspirates in preoperative localization of parathyroid adenomas and in directing surgical approach. Clin Endocrinol. 2006; 65:106-113.
29. Lo CY, Lang BH, Chan W.F., et al. A prospective evaluation of pre-operative localization by technetium-99m-sestamibi scintigraphy and ultrasonography in primary hyperparathyroidism. Am J Surg. 2007; 193:155-159.
30. Geatti O, Shapiro B, Orsolon P.G., et al. Localization of parathyroid enlargement: experience with technetium-99m methoxyisobutylisoni-trile and thallium-201 scintigraphy, ultrasonography and computed tomography. Eur J Nucl Med. 1994; 21:17-22.
31. Berber E, Parikh RT, Ballem N, et al. Factors contributing to negative parathyroid localization: an analysis of 1000 patients. Surgery. 2008; 144:74-79.
32. Johnston LB, Carroll MJ, Britton K.E., et al. The accuracy of parathyroid gland localization in primary hyperparathyroidism using sestamibi radionuclide imaging. J Clin Endocrinol Metab. 1996:81:346-352.
33. Jones JM, Russell CF, Ferguson W.R., Laird JD. Preoperative sestamibi-technitium subtraction scintigraphy in primary hyperpara-thyroidism: experience with 156 consecutive patients. Clin Radiol. 2001; 56:556-559.
34. Chen H, Mack E, Starling JR. A comprehensive evaluation of perioperative adjuncts during minimally invasive parathyroidectomy: which is most reliable? Ann Surg. 2005; 242:375-380; discussion 380-383
35. Rodgers SE, Hunter GJ, Hambert L.M., et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery. 2006; 140:932-940; discussion 940-941
36. Starker L, Mahajan A, Bjorklund P., et al. 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann Surg Oncol. 2010; 18:1723-1728.
37. Kettle AG, O'Doherty MJ. Parathyroid imaging: how good is it and how should it be done? Semin Nucl Med. 2006; 36:206-211.
38. Mahajan A, Starker LF, Ghita M, et al. Parathyroid four-dimensional computed tomography: evaluation of radiation dose exposure during preoperative localization of parathyroid tumors in primary hyperparathyroidism. World J Surg. 2012; 36:1335-1339.
39. Carling T, Udelsman R Minimally invasive parathyroidectomy. In: Oertli D, Udelsman R, eds. Surgery of the Thyroid and Parathyroid Glands. Berlin, Germany: Springer-Verlag; 2012:477-479.
40. Norman J, Politz D. Five thousand parathyroid operations without frozen section of PTH assays: measuring individual parathyroid gland hormone production in real time. Ann Surg Oncol. 2009; 16: 656-666.
41. Quillo AR, Bumpous JM, Goldstein R.E., et al. Minimally invasive parathyroid surgery, the Norman 20% rule: is it valid? Am Surg. 2011; 77:484-487.
42. Irvin GL 3rd, Dembrow VD, Prudhomme DL. Operative monitoring of parathyroid gland hyperfunction. Am J Surg. 1991; 162:299-302.
43. Richards ML, Thompson GB, Farley D.R., Grant CS. An optimal algorithm for intraoperative parathyroid hormone monitoring. Arch Surg. 2011; 146:280-285.
44. Udelsman R, Donovan P, Shaw C. Cure predictability during parathyroidectomy. World J Surg. 2014; 38:525-533.
45. Westra WH, Pritchett DD, Udelsman R. Intraoperative confirmation of parathyroid tissue during parathyroid exploration: a retrospective evaluation of the frozen section. Am J Surg Pathol. 1998; 22: 538-544.
46. Miccoli P, Materazzi G, Baggiani A., Miccoli M. Mini-invasive video-assisted surgery of the thyroid and parathyroid glands: a 2011 update. J Endocrinol Invest. 2011; 34:473-480.
47. Ikeda Y, Takami H, Nimi M., et al. Endoscopic thyroidectomy and parathyroidectomy by the axillary approach. A preliminary report. Surg Endosc. 2002; 16:92-95.
48. Choe JH, Kim SW, Chung K.W., et al. Endoscopic thyroidectomy using a new bilateral axillo-breast approach. World J Surg. 2007; 31: 601-606.
49. Koh YW, Kim JW, Lee S.W., Choi EC. Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions. Surg Endosc. 2009; 23:2053-2060.
50. Lee KE, Kim HY, Park W.S., et al. Postauricular and axillary approach endoscopic neck surgery: a new technique. World J Surg. 2009; 33:767-772.
51. Landry CS, Grubbs EG, Morris G.S., et al. Robot assisted transaxil-lary surgery (RATS) for the removal of thyroid and parathyroid glands. Surgery. 2011; 149:549-555.
52. Karakas E, Steinfeldt T, Gockel A., et al. Transoral thyroid and parathyroid surgery-development of a new transoral technique. Surgery. 2011; 150:108-115.
53. Udelsman R, Lin Q, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011; 253:585-591.
54. Foley CS, Agcaoglu O, Siperstein A.E., Berber E. Robotic transaxil-lary endocrine surgery: a comparison with conventional open technique. Surg Endosc. 2012; 26:2259-2266.
55. Boccara G, Guenoun T, Aidan P. Anesthetic implications for robot-assisted transaxillary thyroid and parathyroid surgery: a report of twenty cases. J Clin Anesth. 2013; 25:508-512.
56. Saunders BD, Wainess RM, Dimick J.B., et al. Who performs endocrine operations in the United States? Surgery. 2003; 134:924-931.
57. Mitchell J, Milas M, MD, Barbosa G, et al. Avoidable reoperations for thyroid and parathyroid surgery: effect of hospital volume. Surgery. 2008; 144:899-907.
58. Chen H, Wang TS, Yen TWF, et al. Operative failures after para-thyroidectomy for hyperparathyroidism: the influence of surgical volume. Ann Surg. 2010; 252:691-695.
59. Malmaeus J, Granberg P-O, Halvorsen J, et al. Parathyroid surgery in Scandinavia. Acta Chir Scand. 1988; 154:409-413.
60. Bergenfelz A, Jansson S, Martensson H., et al. Scandinavian quality register for thyroid and parathyroid surgery: audit of surgery for primary hyperparathyroidism. Langenbecks Arch Surg. 2007; 392:445-451.
61. Slepavicius A, Beisa V, Janusonis V., Strupas K. Focused versus conventional parathyroidectomy for primary hyperparathyroidism: a prospective, randomized, blinded trial. Langenbecks Arch Surg. 2008; 393:659-666.
62. Miccoli P, Berti P, Materazzi G., et al. Endoscopic bilateral neck exploration versus quick intraoperative parathormone assay (qPTHa) during endoscopic parathyroidectomy: a prospective randomized trial. Surg Endosc. 2008; 22:398-400.
63. Aarum S, Nordenstrom J, Reihner E., et al. Operation for primary hyperparathyroidism: the new versus the old order. A randomised controlled trial of preoperative localisation. Scand J Surg. 2007; 96: 26-30.
64. Sozio A, Schietroma M, Franchi L., et al. Parathyroidectomy: bilateral exploration of the neck versus minimally invasive radioguided treatment. Minerva Chir. 2005; 60:83-89.
65. Bergenfelz A, Kanngiesser V, Zielke A., et al. Conventional bilateral cervical exploration versus open minimally invasive parathyroidec-tomy under local anaesthesia for primary hyperparathyroidism. Br J Surg. 2005; 92:190-197.
66. Bergenfelz A, Lindblom P, Tibblin S., Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg. 2002; 236:543-551.
67. Westerdahl J, Bergenfelz A. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: five-year follow-up of a randomized controlled trial. Ann Surg. 2007; 246:976-980.
68. Miccoli P, Bendinelli C, Berti P., et al. Video-assisted versus conventional parathyroidectomy in primary hyperparathyroidism: a prospective randomized study. Surgery. 1999; 126:1117-1121.
69. Starker LF, Bjorklund P, Theoharis C., Long WD 3rd, Carling T, Udelsman R. Clinical and histopathological characteristics of hyperparathyroidism-induced hypercalcemic crisis. World J Surg. 2011; 35:331-335.
70. Udelsman R, Donovan PI. Remedial parathyroid surgery: changing trends in 130 consecutive cases. Ann Surg. 2006; 244:471-479.
71. Prescott JD, Udelsman R. Remedial operation for primary hyper-parathyroidism. World J Surg. 2009; 33:2324-2334.
72. Udelsman R. Approach to the patient with persistent or recurrent primary hyperparathyroidism. J Clin Endocrinol Metab. 2011; 96: 2950-2958.
73. Hessman O, Stalberg P, Sundin A., et al. High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J Surg. 2008; 32:774-781.
74. Starker LF, Akerstrom T, Song W.D., et al. Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism. Horm Cancer. 2012; 3:44-51.
75. Bassett JH, Forbes SA, Pannett A.A., et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet. 1998; 62:232-244.
76. Kulke MG, Benson AB, Bergsland E, et al. Neuroendocrine tumors. In: NCCN Oncology Clinical Practice Guidelines in Oncology (NCCN Guidelines), v.2.2013. Fort Washington, PA: NCCN; 2013. Available at: www.nccn.org./professionals/physician-gls/PDF/neuroendocrine.pdf. Accessed September 30, 2013.
77. Hellman P, Skogseid B, Oberg K., et al. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery. 1998; 124:993-999.
78. Elaraj DM, Skarulis MC, Libutti S.K., et al. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery. 2003; 134:858-864; discussion 864-855
79. Kivlen MH, Bartlett DL, Libutti S.K., et al. Reoperation for hyper-parathyroidism in multiple endocrine neoplasia type 1. Surgery. 2001; 130:991-998.
80. Lambert LA, Shapiro SE, Lee J.E., et al. Surgical treatment of hyper-parathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg. 2005; 140:374-382.
81. Eng C, Clayton D, Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996; 276:1575-1579.
82. Skinner MA, Norton JA, Moley J.F., et al. Heterotopic autotransplantation of parathyroid tissue in children undergoing total thyroidectomy. J Pediatr Surg. 1997; 32:510-513.
83. Kouvaraki M, Perrier N, Shapiro S., et al. Surgical treatment of multiple endocrine neoplasia type 2 (MEN-2). In: Pollock R, Curley S, Ross M, et al., eds. Advanced Therapy in Surgical Oncology. Hamilton, ON: BC Decker Inc.; 2008:465-473.
84. Wassif WS, Moniz CR, Friedman E, et al. Familial isolated hyper-parathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab. 1993; 77:1485-1489.
85. Haven CJ, Wong FK, Van Dam EW, et al. A genotypic and histo-pathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 2000; 85:1449-1454.
86. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002; 32:676-680.
87. Simonds WF, James-Newton LA, Agarwal S.K., et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine. 2002; 81:1-26.
88. Warner J, Epstein M, Sweet A., et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet. 2004; 41:155-160.
89. Cetani F, Pardi E, Ambrogini E., et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol. 2006; 64:146-152.
90. Cole DE, Janicic N, Salisbury S.R., Hendy GN. Neonatal severe hy-perparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: multiple different phenotypes associated with an inactivating Alu insertion mutation of the calcium-sensing receptor gene. Am J Med Genet. 1997; 71:202-210.
91. Carling T, Szabo E, Bai M., et al. Familial hypercalcemia and hyper-calciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab. 2000; 85:2042-2047.
92. Scabo E, Carling T, Hessman O., Rastad J. Loss of heterozygosity in parathyroid glands of familial hypercalcemia with hypercalciuria and point mutation in calcium receptor. J Clin Endocrinol Metab. 2002; 87:3961-3965.
93. Wilhelm-Bals A, Parvex P, Magdelaine C., Girardin E. Successful use of bisphosphonate and caclimimetic in neonatal severe primary hy-perparathyroidism. Pediatrics. 2012; 129:e812-e816.
94. Waller S, Kurzawinski T, Spitz L., et al. Neonatal severe hyperpara-thyroidism: genotype/phenotype correlation and the use of pamidro-nate as rescue therapy. Eur J Pediatr. 2004; 163:589-594.
95. Matsuoka S, Tominaga Y, Sato T., et al. Recurrent renal hyperpara-thyroidism caused by parathyromatosis. World J Surg. 2007; 31:299-305.
96. Tublin ME, Yim JH, Carty SE. Recurrent hyperparathyroidism secondary to parathyromatosis: clinical and imaging findings. J Ultrasound Med. 2007; 26:847-851.
97. Shen WT. Parathyromatosis and parathyroid cancer. Cancer Treat Res. 2010; 153; 105-116.
98. Hundahl SA, Fleming ID, Fremgen A.M., Mench HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999; 86:538-544.
99. Shattuck TM, Valimaki S, Obara T., et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003; 349:1722-1729.
100. Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine. 1992; 71:197-205.
101. Clayman GL, Gonzalez HE, El-Naggar A, Vassilopoulou-Sellin R. Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer. 2004; 100:900-905.